Ortho Biologics

Ortho Biologics was a significant joint venture established between Amgen and Johnson & Johnson (specifically through its subsidiary Ortho Pharmaceutical) to manage the development and commercialization of erythropoietin (EPO). The partnership was centered around the blockbuster drug Epoetin alfa, marketed by Johnson & Johnson as Procrit and Eprex. The company played a pivotal role in the early biologics era, navigating complex licensing agreements and regulatory pathways for one of the first major recombinant protein therapies. While the joint venture's primary functions have since been integrated back into the parent organizations or resolved through legal settlements, it remains a landmark entity in the history of biotech partnerships.